Original Research

Published on 12 Jul 2023

Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence

in Thoracic Oncology

Angela Davey
Maria Thor
Marcel van Herk
Corinne Faivre-Finn
Andreas Rimner
Joseph O. Deasy
Alan McWilliam

Frontiers in Oncology

doi 10.3389/fonc.2023.1156389

1,531 views
2 citations

Case Report

Published on 10 Jul 2023

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity

in Thoracic Oncology

Nicoletta Staropoli
Angela Salvino
Federica Falcone
Valentina Farenza
Martina Costa
Giacomo Rossini
Francesco Manti
Antonella Crispino
Caterina Riillo
Domenico Ciliberto

Frontiers in Oncology

doi 10.3389/fonc.2023.1145986

3,956 views
2 citations

Case Report

Published on 10 Jul 2023

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report

in Thoracic Oncology

Daniela Scattolin
Elena Scagliori
Antonio Scapinello
Alberto Fantin
Valentina Guarneri
Giulia Pasello

Frontiers in Oncology

doi 10.3389/fonc.2023.1201599

2,014 views
3 citations

Systematic Review

Published on 06 Jul 2023

Detection of KRAS mutation using plasma samples in non-small-cell lung cancer: a systematic review and meta-analysis

in Thoracic Oncology

Peiling Cai
Bofan Yang
Jiahui Zhao
Peng Ye
Dongmei Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1207892

1,769 views

Case Report

Published on 05 Jul 2023

Lung adenocarcinoma with bladder metastasis: A case report and literature review

in Thoracic Oncology

Yuying Liu
Xinyue Dong
Tao Li
Yanke Xing
Na Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1202885

3,191 views

Clinical Trial

Published on 05 Jul 2023

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC

in Thoracic Oncology

Christian Wilhelm Langberg
Henrik Horndalsveen
Åslaug Helland
Vilde Drageset Haakensen

Frontiers in Oncology

doi 10.3389/fonc.2023.1217424

1,888 views
2 citations

Original Research

Published on 05 Jul 2023

Leptospermum extract (QV0) suppresses pleural mesothelioma tumor growth in vitro and in vivo by mitochondrial dysfunction associated apoptosis

in Thoracic Oncology

Huaikai Shi
Le Zhang
Ta-Kun Yu
Ling Zhuang
Helen Ke
Ben Johnson
Emma Rath
Kenneth Lee
Sonja Klebe
Steven Kao

Frontiers in Oncology

doi 10.3389/fonc.2023.1162027

2,484 views
1 citation

Original Research

Published on 05 Jul 2023

A five-collagen-based risk model in lung adenocarcinoma: prognostic significance and immune landscape

in Thoracic Oncology

Lingjun Dong
Linhai Fu
Ting Zhu
Yuanlin Wu
Zhupeng Li
Jianyi Ding
Jiandong Zhang
Xiang Wang
Junjun Zhao
Guangmao Yu

Frontiers in Oncology

doi 10.3389/fonc.2023.1180723

3,338 views
3 citations

Original Research

Published on 05 Jul 2023

Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study

in Thoracic Oncology

Helen Brooks
Ling Li
Alfredo Addeo
Megan Stevens
Charles Comins
Sebastian Oltean

Frontiers in Oncology

doi 10.3389/fonc.2023.1197037

1,354 views

Original Research

Published on 04 Jul 2023

Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients

in Thoracic Oncology

Jizheng Tian
Lili Sui
Hong Wang
Xiaoyan Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1180735

1,337 views
2 citations

Original Research

Published on 04 Jul 2023

Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience

in Thoracic Oncology

Paolo Borghetti
Giulia Volpi
Giorgio Facheris
Gianluca Cossali
Eneida Mataj
Salvatore La Mattina
Navdeep Singh
Jessica Imbrescia
Marco Lorenzo Bonù
Davide Tomasini

Frontiers in Oncology

doi 10.3389/fonc.2023.1208204

3,829 views
3 citations

Case Report

Published on 03 Jul 2023

Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report

in Thoracic Oncology

Aurélie Louvet
Natasha Honoré
Anne-France Dekairelle
Cédric Van Marcke
Jean-Charles Goeminne

Frontiers in Oncology

doi 10.3389/fonc.2023.1143775

1,807 views

Original Research

Published on 30 Jun 2023

A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses

in Thoracic Oncology

Wenlong Zhang
Chuzhong Wei
Fengyu Huang
Wencheng Huang
Xiaoxin Xu
Xiao Zhu

Frontiers in Oncology

doi 10.3389/fonc.2023.1104137

2,931 views
8 citations

Case Report

Published on 28 Jun 2023

Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports

in Thoracic Oncology

Lionel Michaux
Alexandre Perrier
Camille Mehlman
Hussa Alshehhi
Antonin Dubois
Roger Lacave
Florence Coulet
Jacques Cadranel
Vincent Fallet

Frontiers in Oncology

doi 10.3389/fonc.2023.1182558

2,528 views
4 citations

Original Research

Published on 27 Jun 2023

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC

in Thoracic Oncology

Qian Wang
Tao Yu
Zi-Hao Ke
Fu-Feng Wang
Jia-Ni Yin
Yang Shao
Kai-Hua Lu

Frontiers in Oncology

doi 10.3389/fonc.2023.1172728

2,817 views
2 citations

Original Research

Published on 23 Jun 2023

Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution

in Thoracic Oncology

Jun Liu
Yaxin Ji
Xiaodan Weng
Wei Shao
Jiaping Zhao
Hanlin Chen
Lu Shen
Fufeng Wang
Qi Meng
Xue Wu

Frontiers in Oncology

doi 10.3389/fonc.2023.1150098

2,291 views
1 citation

Navigation group

Articles

Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report

Detection of KRAS mutation using plasma samples in non-small-cell lung cancer: a systematic review and meta-analysis

Lung adenocarcinoma with bladder metastasis: A case report and literature review

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC

Leptospermum extract (QV0) suppresses pleural mesothelioma tumor growth in vitro and in vivo by mitochondrial dysfunction associated apoptosis

A five-collagen-based risk model in lung adenocarcinoma: prognostic significance and immune landscape

Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study

Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients

Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience

Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report

A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses

Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC

Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution